GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Total Inventories

EYPT (EyePoint Pharmaceuticals) Total Inventories : $2.81 Mil (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Total Inventories?

EyePoint Pharmaceuticals's total inventories for the quarter that ended in Sep. 2024 was $2.81 Mil. EyePoint Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $3.24 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. EyePoint Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $3.24.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. EyePoint Pharmaceuticals's Days Inventory for the three months ended in Sep. 2024 was 401.64.

Inventory Turnover measures how fast the company turns over its inventory within a year. EyePoint Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.23.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. EyePoint Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.31.


EyePoint Pharmaceuticals Total Inventories Historical Data

The historical data trend for EyePoint Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Total Inventories Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 5.34 3.62 2.89 3.91

EyePoint Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.58 3.91 4.26 3.67 2.81

EyePoint Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


EyePoint Pharmaceuticals  (NAS:EYPT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

EyePoint Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

Net-Net Working Capital Per Share (Q: Sep. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(253.793+0.75 * 0.378+0.5 * 2.807-82.183
-0-0)/53.5244
=3.24

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

EyePoint Pharmaceuticals's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2024 )/Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=3.2395/0.736*365 / 4
=401.64

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

EyePoint Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2024 ) / Average Total Inventories (Q: Sep. 2024 )
=0.736 / 3.2395
=0.23

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

EyePoint Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=3.2395 / 10.524
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


EyePoint Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Executives
Goran Ando director
Wendy F Dicicco director
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Nancy Lurker director, officer: President and CEO PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
David R Guyer director ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
David Scott Jones officer: SVP & Chief Commercial Officer C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
Dario A. Paggiarino officer: Chief Medical Officer 4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Ye Liu director ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Michael Craig Pine officer: Chief Corp Dev.&Strat. Officer C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p. 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Anthony P Adamis director 3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension 10 percent owner 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston officer: Chief Financial Officer 124 CHATHAM STREET, CHATHAM NJ 07928
John B. Landis director 1700 KENT AVENUE, WEST LAFAYETTE IN 46906